GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Tax Provision

Chimeric Therapeutics (ASX:CHM) Tax Provision : A$0.09 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Tax Provision?

Chimeric Therapeutics's tax provision for the six months ended in Dec. 2023 was A$0.07 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.09 Mil.

Chimeric Therapeutics Tax Provision Historical Data

The historical data trend for Chimeric Therapeutics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Tax Provision Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
Tax Provision
- -0.16 -0.09

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Tax Provision Get a 7-Day Free Trial - -0.16 -0.10 0.01 0.07

Chimeric Therapeutics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chimeric Therapeutics (ASX:CHM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Tax Provision
Comparable Companies
ASX:TRP ASX:VBS ASX:IMC ASX:PAB ASX:ATX ASX:KZA ASX:ATH ASX:IXC ASX:BGT ASX:ACR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
CHMMF:USA
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Website
https://www.chimerictherapeutics.com
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines